Product Description
BC-819 (inodiftagene vixteplasmid) is a recombinant DNA plasmid that directs the expression of a potent toxin specifically in malignant cells but not in normal tissue. It has been designed to exploit the established biology of the H19 gene, which is upregulated and expressed at high levels only in malignant cells, to produce bacterial diphtheria toxin only in bladder cancer tissue. BC-819 is administered directly into the bladder to enable maximal topical exposure to target bladder cancer cells. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03719300)
Mechanisms of Action: Gene Therapy,H19
Novel Mechanism: Yes
Modality: Gene Therapy
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: ChemomAb
Company Location: TEL AVIV L3 6158002
Company CEO: Dale Pfost
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Adenocarcinoma|Pancreatic Cancer|Bladder Cancer|Muscle Cancer
Phase 1: Bladder Cancer|Transitional Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| BC-BLAD-01 | P1 |
Completed |
Transitional Cell Carcinoma|Bladder Cancer |
2015-10-01 |
2019-03-19 |
Treatments |
|
| Codex | P2 |
Terminated |
Bladder Cancer|Muscle Cancer |
2019-11-18 |
50% |
2020-08-20 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Trial Status |
| LAPC-BC-819 | P2 |
Terminated |
Adenocarcinoma|Pancreatic Cancer |
2013-01-01 |
2019-11-02 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/14/2021 |
News Article |
Gene Therapy R&D and Revenue Forecasts 2020-2030 |
|
09/23/2019 |
News Article |
Anchiano Therapeutics Enters into An Exclusive Option To License Agreement for Novel Pan-RAS Inhibitor and PDE10/Ī²-catenin Inhibitor Programs |
|
09/20/2019 |
News Article |
Anchiano Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference |
|
03/14/2019 |
News Article |
Anchiano Therapeutics Initiates Process to Voluntarily Delist its Ordinary Shares from the Tel Aviv Stock Exchange |